RUNX1 isoform imbalance drives ML-DS, VWF-binding RNA aptamer for hemophilia A treatment, and EZH1/2 inhibitor valemetostat in relapsed/refractory ATL
Blood Podcast
00:00
Acute Megacaryoblastic Leukemia (MLDS)
RUNX-1A had an increased affinity for the MIK-Co-factor MAX. Researchers were able to validate that by genetically interfering with MAX expression. Findings may have broad therapeutic potential even beyond MLDS, says Sebastian Malinge of Telethon Kids Institute in Australia. The next research article is entitled Von Willabrand Factor Binding Aptomer-Run Daptovon Pegel as treatment for severe and non-severe hemophilia A.
Transcript
Play full episode
